A Retrospective Study of S-1 Monotherapy as Second-line Treatment for Patients with Advanced Biliary Tract Cancer

Phase 0 microdose trial to identify chemoresistance in lung and bladder cancer.

(2017) P. T. Henderson et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

(2010) T Okusaka et al.   BRITISH JOURNAL OF CANCER

Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine

(2010) Takashi Sasaki et al.   INVESTIGATIONAL NEW DRUGS

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study

(2010) Birgit Gruenberger et al.   LANCET ONCOLOGY

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Second-Line Treatment With a Combination of Continuous 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Conti-Fam) in Gemcitabine-Pretreated Pancreatic and Biliary Tract Cancer

(2009) Suee Lee et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers

(2009) Maria S. Pino et al.   ONCOLOGY

S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study

(2008) Junji Furuse et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY